Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327704 | 1.00 | SLC7A5 (0.50) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL9848020 | 0.87 | ALOX15 (0.45) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL9847956 | 0.86 | MEN1 (0.42) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL2265488 | 0.85 | USP2 (0.44) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL5323495 | 0.81 | USP2 (0.49) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL5323497 | 0.81 | USP2 (0.49) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL7818681 | 0.80 | GRB2 (0.45) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL7818683 | 0.80 | GRB2 (0.45) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL5324409 | 0.79 | SIRT5 (0.59) | SLC7A5USP2MEN1KMT2AALOX15 | |
| SCHEMBL5324405 | 0.79 | SIRT5 (0.59) | SLC7A5USP2MEN1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-12065511-B2 | Aromatic-cationic peptides and uses of same | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-4760180-A | N-terminally substituted dipeptide amides | G. D. SEARLE & CO. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0213481-A2 | N-terminally substituted dipeptide amides No. 2 | G.D. Searle & Co. (US) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | ARG2, OAT, PDF | SLC7A5 330/4885USP2 3260/4885MEN1 3596/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | SLC7A5 2948/4885USP2 1836/4885MEN1 4313/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | SLC7A5 2849/4885USP2 2999/4885MEN1 3550/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | SLC7A5 2948/4885USP2 1836/4885MEN1 4313/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC7A5 3712/4885USP2 3792/4885MEN1 927/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | SLC7A5 1049/4885USP2 3048/4885MEN1 3607/4885 |
| US-12065511-B2 | Aromatic-cationic peptides and uses of same | ARG2, OAT, PDF | SLC7A5 330/4885USP2 3260/4885MEN1 3596/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | SLC7A5 758/4885USP2 2211/4885MEN1 1808/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | SLC7A5 4605/4885USP2 1573/4885MEN1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.